Fragrance Allergen Labelling: What Changed, and What a 2026 Launch Must Do

Key takeaways

1. The European Union expanded the fragrance allergens that require individual declaration on cosmetic labels, taking the list to more than 80 substances ^[2].
2. New products placed on the market after 31 July 2026 must comply with the expanded declaration.
3. Products placed on the market before that date may continue to be made available until 31 July 2028, which is why the same product can be compliant and non-compliant depending on when it was first supplied.
4. Rebranding, repackaging or reformulating a value line can be treated as placing a new product on the market, so a routine pack refresh may remove any transition benefit.
5. The declaration thresholds did not change; what changed is the length of the list of substances subject to them.
6. Safety opinions on fragrance materials continue to inform later amendments, so allergen compliance is a recurring review rather than a one-off project ^[3].
7. Industry guidance is a practical way to interpret the requirements, but the market's own rules and the responsible person's judgement set the standard ^[1].

The change is easier to manage when it is treated as a timetable rather than as a rule. The expanded declaration list has a placing-on-market date and a making-available date, and those two dates describe different situations for the same product.

This article is written for a product manager planning a launch and a first reorder across the changeover. It focuses on the sequence of decisions, because the technical work of checking a formula is straightforward once the dates are understood, and expensive when they are not.

The dates and what each one actually governs

The first action for a value line is not to relabel everything. It is to establish, product by product, which date each item is governed by.

What did not change

The threshold logic that makes allergen declaration conditional on concentration is unchanged. A substance on the list is declared when it is present above the applicable limit, and the limit depends on whether the product is left on the skin or rinsed off. The change is in the length of the list, not in the way the trigger works.

That distinction matters because it explains why some products need almost no work. A formula that already declared its allergens conservatively, and whose fragrance compound is documented in full, often needs only a check of names and concentrations against the expanded list. A formula whose declaration was assembled from a supplier's summary and a previous pack needs the full exercise, and that is where the schedule risk sits.

It is worth being precise with suppliers about this. The question is not "are you compliant with the new allergen rules" but "can you give me the declared substance list for this compound, in reference nomenclature, with concentrations or threshold flags". The first question invites a yes; the second produces a document that can be checked.

Why rebranding is the quiet trap for value lines

Value lines refresh packaging more often than premium lines. A new look, a new size or a reformulation for cost reasons can all be treated as placing a new product on the market, which means the expanded declaration applies immediately rather than at the end of the transition. A pack refresh planned for 2027 should therefore be checked against the labelling requirement at the design stage, not after the artwork is signed off.

What a launch should do differently now

First, put the allergen statement on the critical path. In most launch plans it sits at the end, after artwork and before print, which is the worst place for a document that depends on the formula. Move the request for the declaration to the sampling stage, so that any required change to the fragrance is a development decision rather than a reprint.

Second, treat the label as a versioned document tied to a formula version. When a value line sourced from a a Chinese fragrance house changes compound supplier or dosage, the declaration must move with it. Version control is unglamorous and is the single most effective control a brand can put in place.

Third, keep the market list attached to the product file. A market that is added after launch brings its own labelling and notification requirements, and the allergen statement is one of the items that has to be reviewed. Brands that sell through distributors should confirm who holds the file and who is responsible for that review locally.

Fourth, decide how the change is communicated to retail. Buyers and distributors will ask whether the product is compliant with the new rules, and the useful answer is a document rather than an assurance. Where the line is produced under a private label arrangement, the brand should confirm with its private label fragrance manufacturer which party issues that document and how quickly it can be produced for a specific order.

Finally, build the review into the calendar rather than into a project. Allergen requirements have changed before and will change again as safety opinions evolve, so the practical target is a file that can be updated in days. Knowing the manufacturing history behind a product makes that easier: a producer able to show Xuelei's manufacturing background across a long period of work is more likely to hold the records a review will ask for.

None of these four actions is expensive. Their absence, however, is what turns a labelling change into a launch delay, and value lines, with their thinner margins and faster pack cycles, feel it first.

Frequently asked questions